Back to News & Events

Immunovent Wins “Best of the Best” in 1st Pitch Life Science Competition

Immunovent, a New York City based diagnostic start-up focusing on the commercialization of novel technologies for diagnosing allergies, was chosen as the “Best of the Best” among previous winners of Mid-Atlantic Bio Angels (MABA)1st Pitch Life Science events in 2014. Seven companies competed for the title of ?Best of the Best?.

Immunovent is developing a platform technology called the Local Antibody Mucosal Brush Diagnostic (LAMB-Dx). It is a needle-free allergy test that works with minute cell samples that are easily and painlessly collected with a soft brush. A proprietary process is then used to detect the specific proteins in the samples that indicate the presence of a food or airborne allergy.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3721 [post_author] => 3 [post_date] => 2021-03-29 13:10:24 [post_date_gmt] => 2021-03-29 13:10:24 [post_content] =>

BARDA DRIVe is seeking information on developments in anticoagulation drugs, assays, and management in the specific context of extracorporeal membrane oxygenation (ECMO) therapy. The intent is to identify areas of innovation that can solve the challenges posed by anticoagulation in ECMO or improve on the ways this issue is currently being addressed. BARDA will not execute any awards based on this notice. This RFI solely aims to gather knowledge on present and future capabilities and other pertinent marketplace data to strengthen BARDA’s understanding of the current developmental landscape of this field. This does not constitute a Request for Proposal (RFP). More information can be found here:
https://beta.sam.gov/opp/e9e7f046d7234dae9f14c1b38a5a20f9/view

The RFI will be open until 04 May 2021, and interested companies should submit their responses to DRIVeContracting@hhs.gov.


[post_title] => BARDA: Call for Information [post_excerpt] => BARDA DRIVe is seeking information on developments in anticoagulation drugs, assays, and management in the specific context of extracorporeal membrane oxygenation (ECMO) therapy. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => barda-call-for-information [to_ping] => [pinged] => [post_modified] => 2021-09-20 16:11:14 [post_modified_gmt] => 2021-09-20 16:11:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3721 [menu_order] => 51 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3540 [post_author] => 3 [post_date] => 2020-05-05 12:48:44 [post_date_gmt] => 2020-05-05 12:48:44 [post_content] => The National Institute on Drug Abuse (NIDA) has announced the 5th “$100,000 for Start a SUD Startup” Challenge. The Challenge goal is to support research ideas that would further an understanding of Substance Use Disorders (SUD) and that are intended to be the foundation for the development of successful new startups. NIDA expects that the contest will enable participants to test the premise that their research idea can be fostered into a biotech startup, and that eventually the newly created startups will contribute to the pool of innovative small business companies that can successfully compete for NIDA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. The Challenge will offer up to ten awards of $10,000 each and technical expertise and mentoring from NIDA scientific research entrepreneurship experts. The Challenge total purse is up to $100,000. Submission Due Date: May 26, 2020, 5:00 p.m. ET. Judging Period: May 27, 2020 to June 15, 2020. Winners Announced: June 22, 2020. View full details about the challenge here: https://www.challenge.gov/challenge/2020-1000000-start-a-sud-startup-challenge/ [post_title] => NIDA/ NIH Challenge "Start a SUD Startup" [post_excerpt] => Challenge goal is to support research ideas that would further an understanding of Substance Use Disorders (SUD) and that are intended to be the foundation for the development of successful new startups. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => nida-nih-challenge-start-a-sud-startup [to_ping] => [pinged] => [post_modified] => 2020-05-05 12:48:44 [post_modified_gmt] => 2020-05-05 12:48:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3540 [menu_order] => 68 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2253 [post_author] => 3 [post_date] => 2016-06-16 16:15:26 [post_date_gmt] => 2016-06-16 16:15:26 [post_content] => regenix_web1Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline. In connection with the financing, Nilesh Kumar of Novo Ventures and Antoine Papiernik of Sofinnova Partners will join the Rgenix Board of Directors together with existing members, including Executive Chairman Eric Rowinsky, M.D., Masoud Tavazoie, M.D. Ph.D., Nancy Chang, Ph.D., and Saeed Tavazoie, Ph.D. Read the full press release about Rgenix’s financing here. [post_title] => Rgenix Announces $33M Series B Financing [post_excerpt] => Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => rgenix-announces-33m-series-b-financing [to_ping] => [pinged] => [post_modified] => 2016-06-16 16:17:16 [post_modified_gmt] => 2016-06-16 16:17:16 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2253 [menu_order] => 176 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

BARDA: Call for Information

More Information

NIDA/ NIH Challenge “Start a SUD Startup”

More Information

Rgenix Announces $33M Series B Financing

More Information